Search

The article focuses on the prevalence of COVID-19 vaccine hesitancy among community-dwelling and hospitalized patients with major depressive disorder, bipolar disorder, and schizophrenia in China.

Background: Clozapine treatment increases the risk of agranulocytosis, but findings on the epidemiology of agranulocytosis have been inconsistent. This meta-analysis examined the prevalence of agranulocytosis and related death in clozapine-treated patients. Methods: A literature search in the international (PubMed, PsycINFO, and EMBASE) and Chinese (WanFang, Chinese National Knowledge Infrastructure, and Sinomed) databases was conducted. Prevalence estimates of agranulocytosis and related death in clozapine-treated patients were synthesized with the Comprehensive Meta-Analysis program using the random-effects model. Results: Thirty-six studies with 260 948 clozapine-treated patients published between 1984 and 2018 were included in the meta-analysis. The overall prevalence of agranulocytosis and death caused by agranulocytosis were 0.4% (95% CI 0.3–0.6%) and 0.05% (95% CI 0.03–0.09%), respectively. The prevalence of agranulocytosis was moderated by sample size, study quality, year of publication, and that of data collection. Conclusions: The prevalence of clozapine-associated agranulocytosis is low. Agranulocytosis-related death appears rare. [ABSTRACT FROM AUTHOR]

The article focuses on the potential anti-COVID-19 properties of psychotropic medications, specifically antidepressants like fluvoxamine. Topics include the need to examine the effects of other psychotropic medications, besides fluvoxamine on COVID-19 outcomes; the possible mechanisms of action of antidepressants in improving COVID-19 outcomes; and the suggestion to explore the anti-COVID-19 properties of other psychotropic medications such as antipsychotics and mood stabilizers.

Background: Suicide attempt (SA), which is one of the strongest predictors of completed suicide, is common in major depressive disorder (MDD) but its prevalence across epidemiological studies has been mixed. The aim of this comprehensive meta-analysis was to examine the pooled prevalence of SA in individuals with MDD. Methods: A systematic literature search was conducted in PubMed, Embase, PsycINFO, Web of Science and Cochrane Library from their commencement date until 27 December 2017. Original studies containing data on prevalence of SA in individuals with MDD were analyzed. Results: In all, 65 studies with a total of 27 340 individuals with MDD were included. Using the random effects model, the pooled lifetime prevalence of SA was 31% [95% confidence interval (CI) 27–34%], 1-year prevalence was 8% (95% CI 3–14%) and 1-month prevalence was 24% (95% CI 15–34%). Subgroup analyses revealed that the lifetime prevalence of SA was significantly associated with the patient setting, study region and income level, while the 1-month prevalence of SA was associated with only the patient setting. Conclusion: This meta-analysis confirmed that SA was common in individuals with MDD across the world. Careful screening and appropriate interventions should be implemented for SA in the MDD population. [ABSTRACT FROM AUTHOR]

The article discusses mental health impact on the frontline health professionals involved in caring for the imported cases during Covid-19 pandemic. Topics include goal of this new service was to provide screening tests and medical treatments for the imported COVID-19 cases of mild-to-moderate severity; effective measures to address mental health issues, the prevalence of mental health problems among frontline health professionals had been substantially reduced.

The article focuses on global imperative to combat stigma associated with the coronavirus disease 2019 pandemic. Topics include the COVID-19 pandemic has often been erroneously associated with specific countries, regions, or ethnicities, which could potentially lead to prejudice and discrimination against certain places and people, and the some mass media has held China solely responsible for the rapid global transmission of COVID-19.

The article focuses on tackling the mental health burden of frontline healthcare staff in the COVID-19 pandemic China's experiences. Topics include the frontline healthcare staff are at high risk of mental health problems due to the overwhelming clinical workload, and the online survey in the early stage of the COVID-19 outbreak at the end of January 2020 found that the prevalence of depression, anxiety, insomnia, and distress symptoms.